Menée à partir de l'analyse immunohistochimique d'échantillons tumoraux prélevés sur 20 patients atteints d'un carcinome épidermoïde de la cavité buccale puis menée à l'aide de lignées cellulaires et de xénogreffes, cette étude met en évidence l'intérêt d'une nouvelle sonde fluorescente, dérivée d'un inhibiteur du transporteur de glucose GLUT1, pour détecter précocement des lésions cancéreuses ou guider l'intervention chirurgicale

Novel fluorescent GLUT1 inhibitor for precision detection and fluorescence image-guided surgery in oral squamous cell carcinoma

Tian, Yu ; Tang, Chu ; Shi, Guangyuan ; Wang, Guorong ; Du, Yang ; Tian, Jie ; Zhang, Haizhong

Early detection and complete resection of oral squamous cell carcinoma (OSCC) are crucial to improving patient survival and prognosis. However, specifically targeted imaging probes for OSCC detection are limited. This study aimed to synthesize a novel near-infrared fluorescence (NIRF) probe for precision detection and fluorescence image-guided surgery in OSCC. Bioinformatics data indicated that glucose transporter 1 (GLUT1) is highly expressed in patients with OSCC. We demonstrated high and [...]

A partir d'une revue systématique de la littérature publiée jusqu'en 2020, cette étude analyse les facteurs dosimétriques et cliniques associés à la toxicité pulmonaire due à un traitement par radiothérapie chez les patients ayant survécu à un cancer pédiatrique

Acute and Late Pulmonary Effects After Radiation Therapy in Childhood Cancer Survivors: A PENTEC Comprehensive Review

Briere, Tina Marie ; Agrusa, Jennifer E. ; Martel, Mary K. ; Jackson, Andrew ; Olch, Arthur J. ; Ronckers, Cecile M. ; Kremer, Leontien C. M. ; Constine, Louis S. ; McAleer, Mary Frances

Objectives: The Pediatric Normal Tissue Effects in the Clinic (PENTEC) pulmonary task force reviewed dosimetric and clinical factors associated with radiation therapy (RT)–associated pulmonary toxicity in children. Methods: Comprehensive search of PubMed (1965-2020) was conducted to assess available evidence and predictive models of RT-induced lung injury in pediatric cancer patients (<21 years old). Lung dose for radiation pneumonitis (RP) was obtained from dose-volume histogram (DVH) data. RP [...]

Menée à l'aide d'un modèle murin de mélanome avec métastases pulmonaires et d'un modèle murin de tumeur colique sous-cutanée, cette étude met en évidence l'intérêt thérapeutique de bactéries Escherichia coli administrées par voie orale et capables d'exprimer in situ, à la surface des vésicules de la membrane externe et sous le contrôle d'un promoteur induit par l'arabinose, une protéine de fusion combinant un antigène tumoral et la cytolysine A

Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria

Yue, Yale ; Xu, Jiaqi ; Li, Yao ; Cheng, Keman ; Feng, Qingqing ; Ma, Xiaotu ; Ma, Nana ; Zhang, Tianjiao ; Wang, Xinwei ; Zhao, Xiao ; Nie, Guangjun

The complex gastrointestinal environment and the intestinal epithelial barrier constrain the design and effectiveness of orally administered tumour vaccines. Here we show that outer membrane vesicles (OMVs) fused to a tumour antigen and produced in the intestine by ingested genetically engineered bacteria function as effective tumour vaccines in mice. We modified Escherichia coli to express, under the control of a promoter induced by the monosaccharide arabinose, a specific tumour antigen fused [...]

Menée auprès de 31 patients atteints d'un carcinome hépatocellulaire de stade B (selon la classification "Barcelona Clinic Liver Cancer"), cette étude de cohorte prospective observationnelle évalue l'efficacité, du point de vue de la survie globale, et la toxicité du lenvatinib en traitement de première ligne

A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma

Kobayashi, Satoshi ; Fukushima, Taito ; Ueno, Makoto ; Moriya, Satoshi ; Chuma, Makoto ; Numata, Kazushi ; Tsuruya, Kota ; Hirose, Shunji ; Kagawa, Tatehiro ; Hattori, Nobuhiro ; Watanabe, Tsunamasa ; Matsunaga, Kotaro ; Suzuki, Michihiro ; Uojima, Haruki ; Hidaka, Hisashi ; Kusano, Chika ; Suzuki, Motoko ; Morimoto, Manabu

Background : Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B). However, it often leads to a poor prognosis and decreased hepatic function especially in patients with BCLC substage B2. Lenvatinib (LEN) was demonstrated to be efficacious in these patients in the REFLECT phase 3 trial. We therefore aimed to evaluate the efficacy and safety of LEN as a first-line treatment for the patients [...]

Mené en Chine sur des patients atteints d'une tumeur solide de stade avancé, cet essai non randomisé de phase IA/IB évalue la dose maximale tolérée de MRG003, un conjugué anticorps-médicament ciblant EGFR, et son efficacité du point de vue du taux de réponse objective

Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial

Qiu, Miao-Zhen ; Zhang, Yang ; Guo, Ye ; Guo, Wei ; Nian, Weiqi ; Liao, Wangjun ; Xu, Zhongyuan ; Zhang, Wenxue ; Zhao, Hong-Yun ; Wei, Xiaoli ; Xue, Liqiong ; Tang, Wenbo ; Wu, Yunteng ; Ren, Guoxin ; Wang, Ling ; Xi, Jingle ; Jin, Yongshuai ; Li, Hu ; Hu, Chaohong ; Xu, Rui-hua

Importance : The antibody drug conjugate drug MRG003 comprises an anti–epidermal growth factor receptor (EGFR) humanized immunoglobulin G1 monoclonal antibody that is conjugated with monomethyl auristatin E via a valine-citrulline linker. There is currently insufficient evidence of this drug's safety and efficacy. Objective : To evaluate the safety and maximum tolerated dose of MRG003 in a phase 1a study and investigate the preliminary antitumor activity in EGFR-expressing patients in a phase [...]

Mené sur 201 patients atteints d'une tumeur de stade avancé, cet essai de phase I/II évalue la dose maximale tolérée du vopratélimab (un anticorps anti-ICOS) seul et en combinaison avec le nivolumab, puis analyse ses caractéristiques pharmacocinétiques et pharmacodynamiques

First in Human Phase 1/2 ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS high CD4 T cell populations and predictors of response

Yap, Timothy A. ; Gainor, Justin F. ; Callahan, Margaret K. ; Falchook, Gerald S. ; Pachynski, Russell K. ; LoRusso, Patricia ; Kummar, Shivaani ; Gibney, Geoffrey T. ; Burris, Howard A. ; Tykodi, Scott S. ; Rahma, Osama E. ; Seiwert, Tanguy Y. ; Papadopoulos, Kyriakos P. ; Blum Murphy, Mariela ; Park, Haeseong ; Hanson, Amanda ; Hashambhoy-Ramsay, Yasmin ; McGrath, Lara ; Hooper, Ellen ; Xiao, Xiaoying ; Cohen, Heather ; Fan, Martin ; Felitsky, Daniel ; Hart, Courtney ; McComb, Rachel ; Brown, Karen ; Sepahi, Ali ; Jimenez, Judith ; Zhang, Weidong ; Baeck, Johan ; Laken, Haley ; Murray, Richard ; Trehu, Elizabeth ; Harvey, Christopher J.

Purpose: The First-in-Human Phase 1/2 ICONIC trial evaluated an investigational ICOS agonist, vopratelimab, alone and in combination with nivolumab in patients with advanced solid tumors. Experimental Design: In Phase 1, patients were treated with escalating doses of intravenous vopratelimab alone or with nivolumab. Primary objectives were safety, tolerability, maximum tolerated dose and recommended Phase 2 dose (RP2D). Phase 2 enriched for ICOS+ tumors; patients were treated with vopratelimab [...]

Cette étude analyse les données de l'essai ayant conduit la "Food and Drug Administration" à autoriser l'utilisation du brexucabtagène autoleucel pour traiter les patients adultes atteints d'une leucémie lymphoïde aiguë réfractaire ou récidivante

Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia

Frey, Noelle V

In October 2021, brexucabtagene autoleucel became the first anti-CD19 chimeric antigen receptor T cell product to receive approval from the US Food and Drug Administration to treat adults with relapsed and refractory B cell acute lymphoblastic leukemia (r/r ALL). The approval is based on results from the Zuma-3 trial and significantly widens treatment options for this patient population. In this article we will review outcomes from this study and its implications.

Mené sur 1 291 patients atteints d'un cancer du côlon (durée médian de suivi : 74,7 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité d'une chimiothérapie adjuvante combinant oxaliplatine et fluoropyrimidine dispensée durant 3 ou 6 mois

Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial

Takayuki Yoshino ; Eiji Oki ; Toshihiro Misumi ; Masahito Kotaka ; Dai Manaka ; Tetsuya Eto ; Junichi Hasegawa ; Akinori Takagane ; Masato Nakamura ; Takeshi Kato ; Yoshinori Munemoto ; Fumitaka Nakamura ; Hiroyuki Bando ; Hiroki Taniguchi ; Yasuhiro Sakamoto ; Manabu Shiozawa ; Masayasu Nishi ; Tetsuya Horiuchi ; Hisakazu Yamagishi ; Junichi Sakamoto ; Tsunekazu Mizushima ; Atsushi Ohtsu ; Masaki Mori

PURPOSE : The phase III ACHIEVE trial conducted in Japan was one of six prospective studies included in the International Duration Evaluation of Adjuvant Therapy collaboration, which explored whether 3 months of adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX) therapy would be noninferior to 6 months of treatment in patients with curatively resected stage III colon cancer. We report the final analyses of survival and long-term safety. PATIENTS [...]

Mené sur 63 patients atteints d'un carcinome rénal à cellules claires de stade avancé ou métastatique, cet essai de phase II compare l'efficacité, du point de vue du taux de réponse objective, et la toxicité du nivolumab en monothérapie et d'un traitement combinant durvalumab et MEDI0680 (un anticorps anti-PD-1)

A Randomized Ph2 Study of MEDI0680 in Combination With Durvalumab vs. Nivolumab Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Voss, Martin H. ; Azad, Arun A. ; Hansen, Aaron R. ; Gray, Jhanelle E. ; Welsh, Sarah J. ; Song, Xuyang ; Kuziora, Michael ; Meinecke, Lina ; Blando, Jorge ; Achour, Ikbel ; Wang, Yi ; Walcott, Farzana ; Oosting, Sjoukje F.

Background: MEDI0680 is a humanized anti-programmed cell death-1 (PD-1) antibody and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase 2 study evaluated antitumor activity and safety of MEDI0680 plus durvalumab versus nivolumab monotherapy in immunotherapy naïve patients with advanced clear cell renal cell carcinoma who received at least one prior line of anti-angiogenic therapy. Methods: Patients [...]

Menée à partir de données 2000-2008 d'un registre canadien portant sur 971 patients atteints d'un cancer de l'oropharynx, cette étude analyse l'évolution de l'incidence et de la survie en fonction des traitements reçus et de la présence d'une infection par le papillomavirus humain

Combined chemoradiotherapy showed improved outcome with early-stage HPV-positive oropharyngeal cancers

Lu, X. J. David ; Jackson, Emmanuel ; Chew, Jason ; Nguyen, Sally ; Wu, Jonn ; Poh, Catherine F. ; Prisman, Eitan

Background: The revised 8th Edition American Joint Committee on Cancer (AJCC) Head and Neck Staging Manual distinguishes HPV-mediated from non-HPV-mediated oropharyngeal cancer (OpSCC). The objective was to analyze OpSCC treatment modalities and outcomes. Methods: A retrospective study of OpSCC patients treated with radiotherapy or chemoradiotherapy between January 1st, 2000, and December 31st, 2008, as identified from the BC Cancer Registry. All patients received treatment at cancer clinics [...]

A partir d'une revue de la littérature publiée entre 2000 et 2021, cet article identifie les mécanismes et les manifestations cliniques des lésions cardiaques induites par les traitements puis examine les protocoles permettant d'améliorer la protection cardiaque chez les patients atteints d'un lymphome

An integrated approach to cardioprotection in lymphomas

Maraldo, Maja V. ; Levis, Mario ; Andreis, Alessandro ; Armenian, Saro ; Bates, James ; Brady, Jessica ; Ghigo, Alessandra ; Lyon, Alexander R. ; Manisty, Charlotte ; Ricardi, Umberto ; Aznar, Marianne C. ; Riccardo Filippi, Andrea

In potentially curable cancers, long-term survival depends not only on the successful treatment of the malignancy but also on the risks associated with treatment-related toxicity, especially cardiotoxicity. Malignant lymphomas affect patients at any age, with acute and late toxicity risks that could have a severe effect on morbidity, mortality, and quality of life. Although our understanding of chemotherapy-associated and radiotherapy-associated cardiovascular disease has advanced considerably, [...]